Mindset Pharma to Participate in Upcoming Conferences in December 2022
TORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a...
Mental Health
Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category
NeuroStar’s technology once again recognized as an effective non-drug treatment for patientsMALVERN, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Neuronetics,...
BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, Arizona
VANCOUVER, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Syneos Health Releases 2023 Health Trends
Predicts AI and Machine Learning, Diversity and Medical Affairs will Transform Biopharma Product DevelopmentMORRISVILLE, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) --...
Desjardins Insurance teams up with TELUS Health to expand access to health and wellness services
Over 500,000 Desjardins group insurance plan members will benefit from a suite of health and wellness solutions from TELUS HealthMONTREAL...
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer
- Dr. Kirpekar joins from Otsuka Pharmaceutical where he was Head of Business Development and Co-chair of the Global Business...
CloudMD to Present at Upcoming TD Technology Conference, November 21 – 23, 2022
VANCOUVER, British Columbia, Nov. 18, 2022 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQX: DOCRF, Frankfurt: 6PH)...
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall careSALT LAKE CITY,...
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
NEW YORK and BERLIN, Nov. 17, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical...
Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations
Enhancements further establish the Company’s leadership position as the top transcranial magnetic stimulation therapyMALVERN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE)...
Chilean Healthcare NGOs Release Adaptation of Exhaustive Canadian Obesity Guidelines
Chile launches evidence-based approach to obesity care rooted in Canada’s watershed 2020 clinical practice guidelinesEDMONTON, Alberta, Nov. 14, 2022 (GLOBE...
QHSLab, Inc. Projects a $7.5 Billion Addressable Market for its Integrated Service Program (ISP) Digital Health Solution Designed For Primary Care
This forecast is based on estimates generated through a recent pilot program and scaled through approximately 250,000 independent primary care...
PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at Neuroscience 2022 by the Society for Neuroscience
Seeking guidance from FDA to proceed towards a Phase 3 clinical study of KETARX™ (ketamine) for Parkinson’s disease under the...
Walmart Canada and TELUS Health join forces to provide Walmart associates with comprehensive virtual health and wellbeing services
Over 100,000 associates will benefit from the full suite of TELUS Health’s digital employer health solutions, as retailer becomes first...
VitalHub Corp. Announces Acquisition of Certain Assets to Maintain the Business of ADI Health
TORONTO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) (OTCQX:VHIBF) is pleased to announce...
Acquisition Has Love Pharma’s Naltrexone on NIH Shortlist to Address Unmet Medical Need—Treatment for Long Covid
NEW YORK, NY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Love Pharma Inc. (CSE: LUV) (FSE: G1Q0), an international mental health...
BrainsWay Announces Private Insurance Coverage from Premera Blue Cross for the Treatment of OCD Utilizing Deep TMS™
Reflects Broader Trends Significantly Increasing Access to Deep TMS for OCD and Depression PatientsBURLINGTON, Mass. and JERUSALEM, Nov. 03, 2022...
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD
Study Conducted by Dr. Vince Clinical ResearchKANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a...
QHSLab, Inc. Meets the Demand for Updated Mental Health Screening Recommendations from the U.S. Preventive Services Task Force
The latest recommendations from the U.S. Preventive Services Task Force (USPSTF) indicate that all adults under the age of 65...
BrainsWay Appoints Dr. Colleen A. Hanlon as Vice President of Medical Affairs
Dr. Hanlon has Served as a Leader in Brain Stimulation Research for Nearly 20 YearsBURLINGTON, Mass. and JERUSALEM, Nov. 01,...
